EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study

Takeshi Morimoto, Haruhiko Hoshino iD, Yukako Matsuo, Tatsuki Ibuki, Kayoko Miyata, Yukihiro Koretsune iD

American Journal of Cardiovascular Drugs · 2023

DOI: 10.1007/s40256-023-00611-7 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift American Journal of Cardiovascular Drugs, 2023. Verfasst von Takeshi Morimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan. morimoto@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol-Myers Squibb. K.K., Pfizer Japan Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We previously conducted a retrospective cohort study using chart review of oral anticoagulant-naïve Japanese patients with nonvalvular atrial fibrillation (NVAF) that assessed the risk of major bleeding and stroke/systemic embolism (SE) events of apixaban versus warfarin. METHODS: In this subgroup analysis, we compared the risk of major bleeding and stroke/SE events by stratifying patients into four subgroups matched 1:1 using propensity score matching (PSM) according to baseline creatinine clearance (CrCl; mL/min): ≥ 15 to < 30, ≥ 30 to < 50, ≥ 50 to < 80, and ≥ 80. RESULTS: Of the 7074 patients in the apixaban group and 4998 in the warfarin group eligible for inclusion in the analysis, 4385 were included in each group after PSM. Incidence rates of major bleeding and stroke/SE events were generally lower with apixaban versus warfarin across the CrCl subgroups. When all patients with a CrCl change of < 0 mL/min per year during the study period (apixaban, n = 3871; warfarin, n = 2635) were stratified into four subgroups based on the magnitude of CrCl decline (median CrCl change [mL/min] per year: - 1.09, - 3.48, - 7.54, and - 36.92 for apixaban, and - 1.10, - 3.65, - 7.85, and - 40.40 for warfarin), the incidence rates of major bleeding and stroke/SE events generally increased with an increasing CrCl decline per year in both groups. CONCLUSIONS: In Japanese patients with NVAF, the safety and effectiveness of apixaban and warfarin were consistent across different renal subgroups, including those with severe renal impairment. Our results highlight the importance of monitoring renal function variations over time in patients with NVAF. GOV IDENTIFIER: NCT03765242.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeHumansWarfarinRetrospective StudiesEast Asian PeopleAnticoagulantsPyridonesHemorrhageKidneyRivaroxabanPyrazoles

Substanzen

WarfarinAnticoagulantsPyridonesRivaroxabanapixabanPyrazoles

Autor:innen und Institutionen

  • Department of Clinical Epidemiology, Hyogo Medical University, 1-1 Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan. morimoto@kuhp.kyoto-u.ac.jp.
  • Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan.
  • Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.
  • Cardiovascular Division, National Hospital Organization Osaka National Hospital, Osaka, Japan.

ORCID-Profile: Haruhiko Hoshino, Yukihiro Koretsune

Förderung

  • Bristol-Myers Squibb. K.K.
  • Pfizer Japan Inc.

Zitieren

APA

Morimoto, T., Hoshino, H., Matsuo, Y., Ibuki, T., Miyata, K., & Koretsune, Y. (2023). Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00611-7

Vancouver

Morimoto T, Hoshino H, Matsuo Y, Ibuki T, Miyata K, Koretsune Y. Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study. American Journal of Cardiovascular Drugs. 2023. doi:10.1007/s40256-023-00611-7

BibTeX
@article{Morimoto2023,
  author = {Morimoto, Takeshi and Hoshino, Haruhiko and Matsuo, Yukako and Ibuki, Tatsuki and Miyata, Kayoko and Koretsune, Yukihiro},
  title = {Safety and Effectiveness of Apixaban Versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation Stratified by Renal Function: A Retrospective Cohort Study},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2023},
  doi = {10.1007/s40256-023-00611-7}
}
Kostenlos starten →